[go: up one dir, main page]

ECSP21008112A - Compuestos de pirrolotriazina como inhibidores de tam - Google Patents

Compuestos de pirrolotriazina como inhibidores de tam

Info

Publication number
ECSP21008112A
ECSP21008112A ECSENADI20218112A ECDI202108112A ECSP21008112A EC SP21008112 A ECSP21008112 A EC SP21008112A EC SENADI20218112 A ECSENADI20218112 A EC SENADI20218112A EC DI202108112 A ECDI202108112 A EC DI202108112A EC SP21008112 A ECSP21008112 A EC SP21008112A
Authority
EC
Ecuador
Prior art keywords
pyrrolotriazine compounds
inhibitors
tam inhibitors
compounds
tam
Prior art date
Application number
ECSENADI20218112A
Other languages
English (en)
Inventor
Taisheng Huang
David M Burns
Yun-Long Li
Song Mei
Jincong Zhuo
Hao Feng
Joseph Barbosa
Joseph Glenn
Chunhong He
xiaozhao Wang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of ECSP21008112A publication Critical patent/ECSP21008112A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente solicitud hace referencia a compuestos de Fórmula I, o sales farmacéuticamente aceptable de estos, que son inhibidores de cinasas TAM que resultan útiles para el tratamiento de trastornos tales como cáncer.
ECSENADI20218112A 2016-03-28 2021-02-04 Compuestos de pirrolotriazina como inhibidores de tam ECSP21008112A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314066P 2016-03-28 2016-03-28
US201662362934P 2016-07-15 2016-07-15
US201662438750P 2016-12-23 2016-12-23

Publications (1)

Publication Number Publication Date
ECSP21008112A true ECSP21008112A (es) 2021-07-30

Family

ID=58489114

Family Applications (3)

Application Number Title Priority Date Filing Date
ECSENADI201881153A ECSP18081153A (es) 2016-03-28 2018-10-26 Compuestos de pirrolotriazina como inhibidores de tam
ECSENADI20218112A ECSP21008112A (es) 2016-03-28 2021-02-04 Compuestos de pirrolotriazina como inhibidores de tam
ECSENADI202426455A ECSP24026455A (es) 2016-03-28 2024-04-04 Compuestos de pirrolotriazina como inhibidores de tam

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECSENADI201881153A ECSP18081153A (es) 2016-03-28 2018-10-26 Compuestos de pirrolotriazina como inhibidores de tam

Family Applications After (1)

Application Number Title Priority Date Filing Date
ECSENADI202426455A ECSP24026455A (es) 2016-03-28 2024-04-04 Compuestos de pirrolotriazina como inhibidores de tam

Country Status (31)

Country Link
US (5) US9981975B2 (es)
EP (2) EP4321513A3 (es)
JP (4) JP7034084B2 (es)
KR (3) KR102483020B1 (es)
CN (3) CN109348715B (es)
AU (3) AU2017241524B2 (es)
CL (1) CL2018002759A1 (es)
CO (1) CO2018011550A2 (es)
CR (1) CR20180516A (es)
DK (1) DK3436461T3 (es)
EC (3) ECSP18081153A (es)
ES (1) ES2967866T3 (es)
FI (1) FI3436461T3 (es)
HR (1) HRP20231614T1 (es)
HU (1) HUE064656T2 (es)
IL (2) IL293496B2 (es)
LT (1) LT3436461T (es)
MD (1) MD3436461T2 (es)
MX (1) MX2018011792A (es)
MY (1) MY202022A (es)
PE (1) PE20190175A1 (es)
PH (1) PH12018502102A1 (es)
PL (1) PL3436461T3 (es)
PT (1) PT3436461T (es)
RS (1) RS65129B1 (es)
SG (2) SG11201808582RA (es)
SI (1) SI3436461T1 (es)
SM (1) SMT202300480T1 (es)
TW (3) TWI828027B (es)
UA (1) UA123785C2 (es)
WO (1) WO2017172596A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
EP4321513A3 (en) 2016-03-28 2024-05-08 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
US12023319B2 (en) 2016-12-23 2024-07-02 Bayer Pharma Aktiengesellschaft Carboxylic acid aromatic amides
JOP20190156B1 (ar) 2016-12-23 2023-09-17 Bayer Pharma AG أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1
JP7156287B2 (ja) 2017-08-23 2022-10-19 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
AU2018342471B2 (en) * 2017-09-27 2023-08-24 Incyte Corporation Salts of pyrrolotriazine derivatives useful as TAM inhibitors
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
US20210177828A1 (en) * 2018-01-17 2021-06-17 Nanjing Transthera Biosciences Co., Ltd. Tam family kinase /and csf1r kinase inhibitor and use thereof
WO2019147782A1 (en) 2018-01-26 2019-08-01 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
CN110627796B (zh) * 2018-06-21 2022-07-12 北京越之康泰生物医药科技有限公司 含氮杂环类衍生物及其在医药上的应用
DK3813800T3 (da) 2018-06-29 2025-06-02 Incyte Corp Formuleringer af en axl/mer-hæmmer
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111689991B (zh) * 2019-03-13 2023-06-09 习峰 取代的杂芳基化合物及其组合物和用途
CN110156836A (zh) * 2019-06-10 2019-08-23 成家钢 一种环丙基羰基亚甲基三苯基磷的制备方法
JP7636326B2 (ja) * 2019-07-29 2025-02-26 武田薬品工業株式会社 複素環化合物
CN112409361B (zh) * 2019-08-23 2022-08-16 山东轩竹医药科技有限公司 Tam抑制剂及其用途
AU2020342108B2 (en) 2019-09-06 2024-03-07 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2，1-f][1，2，4]三嗪-4-胺的一种新合成方法
AU2021230385A1 (en) * 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
CN113683629B (zh) * 2020-05-18 2023-07-04 北京范恩柯尔生物科技有限公司 取代的杂芳基化合物及其组合物和用途
WO2022007921A1 (zh) * 2020-07-10 2022-01-13 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
WO2022166610A1 (zh) * 2021-02-05 2022-08-11 四川科伦博泰生物医药股份有限公司 一类哒嗪酮杂环化合物及其制备方法和用途
WO2023016296A1 (zh) * 2021-08-12 2023-02-16 四川科伦博泰生物医药股份有限公司 一类杂环化合物及其制备方法和用途
TW202330519A (zh) * 2021-09-29 2023-08-01 香港商德琪研發有限公司 作為ｔａｍ抑制劑的吡唑并吡啶化合物
WO2023155886A1 (en) * 2022-02-17 2023-08-24 Shanghai Antengene Corporation Limited Pyrazolopyridine compounds as tam inhibitors
WO2024054793A1 (en) 2022-09-09 2024-03-14 University Of Rochester Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4908056A (en) 1986-04-25 1990-03-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0352575A3 (de) 1988-07-28 1991-08-21 Bayer Ag Substituierte anellierte Pyrrole
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH0395163A (ja) 1989-09-08 1991-04-19 Daicel Chem Ind Ltd ２．２．４．４．６―ペンタメチル―２．３．４．５―テトラヒドロピリミジンの製造法
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
IT1269176B (it) 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
EP1047761A1 (en) 1997-10-14 2000-11-02 The Procter & Gamble Company Hard surface cleaning compositions comprising mid-chain branched surfactants
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
AU7491400A (en) 1999-09-17 2001-04-17 Abbott Gmbh & Co. Kg Kinase inhibitors as therapeutic agents
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
EA010184B1 (ru) 2001-04-06 2008-06-30 Уайт Применение противоопухолевых комбинаций рапамицина с гемцитабином или 5-фторурацилом
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
WO2004035580A1 (en) 2002-10-21 2004-04-29 Aprea Ab Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
PL377342A1 (pl) 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
TW200505915A (en) 2003-03-13 2005-02-16 Synta Pharmaceuticals Corp Fused pyrrole compounds
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP4989217B2 (ja) 2003-03-26 2012-08-01 エガレット エイ／エス 薬剤物質の送達制御用マトリックス組成物
KR20120090094A (ko) 2003-06-13 2012-08-16 바이오겐 아이덱 엠에이 인코포레이티드 아글리코실 항-ｃｄ154(ｃｄ40 리간드) 항체 및 이의 용도
FR2857966A1 (fr) 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20050203063A1 (en) 2003-09-12 2005-09-15 Raymond Deshaies Proteasome pathway inhibitors and related methods
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
EP2308879A1 (en) 2004-04-02 2011-04-13 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
TW200613306A (en) * 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MX2007006204A (es) 2004-11-24 2007-06-20 Novartis Ag Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
RS51843B (sr) * 2005-11-17 2012-02-29 Osi Pharmaceuticals Llc. KONDENZOVANI BICIKLIČNI m TOR INHIBITORI
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
JP5193876B2 (ja) 2005-12-02 2013-05-08 バイエル・ヘルスケア・エルエルシー オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体
US8143393B2 (en) * 2005-12-02 2012-03-27 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2343298B9 (en) 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP1960372B1 (en) 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
CA2635231C (en) 2005-12-29 2014-07-15 Abbott Laboratories Protein kinase inhibitors
MX2008013110A (es) 2006-04-12 2009-03-06 Vertex Pharma 4-5-dihidro-[1,2,4]triazolo[4,3-f]pteridinas como inhibidores de la proteina-cinasa plk1 para el tratamiento de trastornos proliferativos.
SI2010528T1 (en) 2006-04-19 2018-02-28 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and procedures for inhibiting CSF-1R signaling
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
WO2008048375A1 (en) 2006-05-19 2008-04-24 Bayer Healthcare Ag Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
CN101506198A (zh) 2006-06-29 2009-08-12 先灵公司 取代的双环和三环凝血酶受体拮抗剂
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
US8097630B2 (en) 2006-10-10 2012-01-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
CN103288833B (zh) * 2006-11-22 2018-01-12 因塞特控股公司 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
EP2428204A3 (en) 2006-12-07 2012-07-04 Schering Corporation pH sensitive matrix formulation
CA2672612A1 (en) 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
ES2672172T3 (es) 2006-12-29 2018-06-12 Rigel Pharmaceuticals, Inc. Triazoles N3-heteroarilsustituidos y triazoles N5-heteroarilsustituidos útiles como inhibidores de Axl
US7872000B2 (en) 2006-12-29 2011-01-18 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as Axl inhibitors
EP2078010B1 (en) 2006-12-29 2014-01-29 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
PT2114980E (pt) 2007-01-12 2012-09-25 Biocryst Pharm Inc Análogos de nucleósidos anti-virais
EP2114983B8 (en) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
CN101652141A (zh) 2007-03-29 2010-02-17 万能药生物有限公司 他克莫司的调节释放剂型
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
ES2393038T3 (es) 2007-05-10 2012-12-18 Biocryst Pharmaceuticals, Inc. Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer
BRPI0823520A2 (pt) 2007-06-12 2013-12-17 Concert Pharmaceuticals Inc Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
EP2178563A2 (en) 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
US20090263397A1 (en) 2007-07-06 2009-10-22 Buck Elizabeth A Combination anti-cancer therapy
AU2008287339A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases
US8138336B2 (en) 2007-09-25 2012-03-20 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR20100089090A (ko) 2007-10-25 2010-08-11 아스트라제네카 아베 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
JP5635909B2 (ja) 2007-10-26 2014-12-03 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な多環アリール置換トリアゾール及び多環ヘテロアリール置換トリアゾール
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
BRPI0910232A2 (pt) 2008-03-19 2015-09-29 Osi Pharm Inc formas de sais inibidores do mtor
ES2391373T3 (es) 2008-04-16 2012-11-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Derivados de quinoleína como inhibidores de la cinasa AXL
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
NZ601453A (en) 2008-06-23 2014-05-30 Vertex Pharma Protein kinase inhibitors
KR20110018376A (ko) 2008-06-23 2011-02-23 스미또모 가가꾸 가부시키가이샤 조성물 및 상기 조성물을 이용하여 이루어지는 발광 소자
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
EP2326641B1 (en) 2008-07-09 2014-09-03 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2730251C (en) 2008-07-09 2016-08-09 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010025073A1 (en) 2008-08-28 2010-03-04 Takeda Pharmaceutical Company Limited Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
EP2350317A4 (en) 2008-10-20 2012-06-27 Univ Colorado Regents BIOLOGICAL MARKERS FOR PREDICTING THE ANTICIPATE RESPONSE TO INSULINARY GROWTH FACTOR 1 RECEPTOR KINASE INHIBITORS
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010071885A1 (en) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010104307A2 (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
JP5656976B2 (ja) * 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
WO2011139273A1 (en) 2010-05-05 2011-11-10 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
CA2766100C (en) * 2009-06-29 2018-05-22 Incyte Corporation Pyrimidinones as pi3k inhibitors
EP2459191A1 (en) 2009-07-31 2012-06-06 OSI Pharmaceuticals, LLC Mtor inhibitor and angiogenesis inhibitor combination therapy
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA201200525A1 (ru) 2009-09-21 2012-09-28 Гайлид Сайэнсиз, Инк. 2'-фторзамещенные карба-нуклеозидные аналоги для противовирусного лечения
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
CN102596979B (zh) 2009-09-21 2014-12-10 吉里德科学公司 用于制备1’-取代碳核苷类似物的方法和中间体
CN103492391A (zh) 2009-09-25 2014-01-01 沃泰克斯药物股份有限公司 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
AU2010303567B2 (en) 2009-10-06 2016-06-09 Millennium Pharmaceuticals, Inc Heterocyclic compounds useful as PDK1 inhibitors
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
ES2627703T3 (es) 2010-01-22 2017-07-31 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Inhibidores de PI3·quinasa
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
JP5752232B2 (ja) * 2010-03-31 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
GB2480814A (en) 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2012012465A1 (en) 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
BR112013001553B1 (pt) 2010-07-22 2021-01-12 Gilead Sciences, Inc. compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
ES2549926T3 (es) 2010-09-29 2015-11-03 Kissei Pharmaceutical Co., Ltd. Derivados (aza)indolizínicos como inhibidores de la xantina-oxidasa
EP2625178A4 (en) 2010-10-08 2014-04-30 Biota Europe Ltd BACTERIA TOPOISOMERASE II FOR INHIBITING 2-ETHYL CARBAMOYLAMINE-1,3-BENZOTHIAZOL-5-YLENE
CN103403010A (zh) 2010-10-08 2013-11-20 依兰制药公司 Polo样激酶的抑制剂
ITRM20100537A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
MX2013010871A (es) 2011-03-23 2014-01-31 Amgen Inc Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3.
US8901120B2 (en) 2011-04-01 2014-12-02 University Of Utah Research Foundation Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase
CN103703174B (zh) 2011-05-04 2017-05-10 因特利凯有限责任公司 联合药物组合物及其用途
WO2012154608A1 (en) 2011-05-06 2012-11-15 Intellikine, Llc Reactive mtor and pi3 kinase inhibitors and uses thereof
DK2710007T3 (da) 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
EP2726482B1 (en) 2011-07-01 2016-07-20 Bayer Intellectual Property GmbH Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
KR102131612B1 (ko) 2011-09-02 2020-07-08 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
PT2758052T (pt) 2011-09-18 2018-03-29 Euro Celtique Sa Composição farmacêutica que compreende um inibidor de hdac e um ciclopolissacárido
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
MX2014004086A (es) 2011-10-03 2014-09-22 Univ North Carolina Compuestos de pirrolopirimidina para el tratamiento del cancer.
CA2854926A1 (en) 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
UA114900C2 (uk) 2011-11-14 2017-08-28 Ігніта, Інк. Похідні урацилу як інгібітори axl і c-met-кінази
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
BR112014012892B1 (pt) 2011-11-29 2022-12-20 Perosphere Inc Compostos de reversão anticoagulante e composição farmacêutica compreendendo os referidos compostos
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
EP2791143B1 (en) 2011-12-15 2016-02-24 Bayer Intellectual Property GmbH Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment of cancer
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
KR102078530B1 (ko) 2012-01-31 2020-02-18 다이이찌 산쿄 가부시키가이샤 피리돈 유도체들
WO2013113097A1 (en) 2012-01-31 2013-08-08 Beta Pharma Canada Inc. Cyclic molecules as bruton's tyrosine kinase inhibitors
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
WO2013162061A1 (ja) 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
MX368112B (es) 2012-06-18 2019-09-18 Principia Biopharma Inc Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias.
EP2861596B1 (en) 2012-06-19 2019-03-20 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9260436B2 (en) 2012-06-22 2016-02-16 Sumitomo Chemical Company, Limited Fused heterocyclic compound
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
ES2889757T3 (es) 2012-09-06 2022-01-13 Plexxikon Inc Compuestos y procedimientos para la modulación de quinasas e indicaciones para estos
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
RU2015115631A (ru) * 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9242988B2 (en) 2012-10-17 2016-01-26 Merck Sharp & Dohme Corp. 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2909210A4 (en) 2012-10-17 2016-04-06 Merck Sharp & Dohme 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP2919785A4 (en) 2012-11-16 2016-10-05 Biocryst Pharm Inc ANTIVIRAL NUCLEOSIDES CONTAINING AZASUCRE
JP6218848B2 (ja) 2012-11-20 2017-10-25 プロキナーゼ ゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのチオエーテル誘導体
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US9926282B2 (en) 2013-01-18 2018-03-27 Bristol-Myers Squibb Company Phthalazinones and isoquinolinones as rock inhibitors
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014130856A2 (en) 2013-02-21 2014-08-28 Wayne Rothbaum Treatment of skeletal-related disorders
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9012466B2 (en) 2013-03-12 2015-04-21 Arqule Inc. Substituted tricyclic pyrazolo-pyrimidine compounds
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
US20210317140A1 (en) 2013-10-18 2021-10-14 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
WO2015066371A1 (en) 2013-10-31 2015-05-07 Forum Pharmaceuticals, Inc. SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
EP3067356B1 (en) 2013-11-08 2018-07-04 ONO Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
WO2015081783A1 (zh) 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
US9840509B2 (en) * 2014-02-03 2017-12-12 Cadila Healthcare Limited Heterocyclic compounds
CN106170488B (zh) 2014-02-12 2020-09-18 弗门尼舍公司 用于取代的1-苄基-3-(1-(异噁唑-4-基甲基)-1h-吡唑-4-基)咪唑烷-2,4-二酮的合成的改进方法
GB201420285D0 (en) 2014-11-14 2014-12-31 Bergenbio As Process
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
SG10201906059VA (en) 2015-07-30 2019-08-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
US20180296561A1 (en) 2015-10-07 2018-10-18 The University Of North Carolina At Chapel Hill The Methods For Treatment Of Tumors
RU2721119C2 (ru) 2015-10-13 2020-05-15 Нихон Нохияку Ко., Лтд. Содержащее оксимную группу конденсированное гетероциклическое соединение или его соль, сельскохозяйственный и садовый инсектицид, содержащий данное соединение, и способ применения данного инсектицида
WO2017083789A1 (en) 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
ES2911678T3 (es) 2015-11-14 2022-05-20 Sunshine Lake Pharma Co Ltd Forma cristalina de un compuesto de quinolina sustituida y composiciones farmacéuticas de la misma
EP4321513A3 (en) 2016-03-28 2024-05-08 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
CR20180553A (es) 2016-04-22 2019-02-01 Incyte Corp Formulaciones de un inhibidor de lsd1
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
CA3030864A1 (en) 2016-07-15 2018-01-18 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of smn2
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
AU2018342471B2 (en) 2017-09-27 2023-08-24 Incyte Corporation Salts of pyrrolotriazine derivatives useful as TAM inhibitors
DK3813800T3 (da) 2018-06-29 2025-06-02 Incyte Corp Formuleringer af en axl/mer-hæmmer
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors

Also Published As

Publication number Publication date
SG11201808582RA (en) 2018-10-30
KR102558066B1 (ko) 2023-07-25
TW202436299A (zh) 2024-09-16
TWI753892B (zh) 2022-02-01
JP7034084B2 (ja) 2022-03-11
SI3436461T1 (sl) 2024-03-29
JP7271750B2 (ja) 2023-05-11
NZ747736A (en) 2024-12-20
SG10202009423QA (en) 2020-11-27
HUE064656T2 (hu) 2024-04-28
TW202241903A (zh) 2022-11-01
KR102483020B1 (ko) 2023-01-04
CN109348715A (zh) 2019-02-15
IL261957A (en) 2018-10-31
CR20180516A (es) 2019-03-05
CO2018011550A2 (es) 2018-12-14
IL293496B1 (en) 2023-01-01
US9981975B2 (en) 2018-05-29
US11591338B2 (en) 2023-02-28
DK3436461T3 (da) 2024-01-02
UA123785C2 (uk) 2021-06-02
TW201738246A (zh) 2017-11-01
IL293496B2 (en) 2023-05-01
EP3436461A1 (en) 2019-02-06
US10844069B2 (en) 2020-11-24
US10442810B2 (en) 2019-10-15
MY202022A (en) 2024-03-29
MD3436461T2 (ro) 2024-05-31
US20240124463A1 (en) 2024-04-18
AU2021245220A1 (en) 2021-11-04
JP2019510043A (ja) 2019-04-11
ES2967866T3 (es) 2024-05-06
KR20230111268A (ko) 2023-07-25
US20170275290A1 (en) 2017-09-28
RS65129B1 (sr) 2024-02-29
AU2021245220B2 (en) 2023-11-23
KR20230008241A (ko) 2023-01-13
US20200131185A1 (en) 2020-04-30
US20180327412A1 (en) 2018-11-15
CN114456175A (zh) 2022-05-10
US12415809B2 (en) 2025-09-16
CL2018002759A1 (es) 2019-02-15
CA3019145A1 (en) 2017-10-05
PT3436461T (pt) 2024-01-23
PE20190175A1 (es) 2019-02-01
JP2022084663A (ja) 2022-06-07
CN109348715B (zh) 2021-12-31
JP7500819B2 (ja) 2024-06-17
KR20190013721A (ko) 2019-02-11
EP3436461B1 (en) 2023-11-01
FI3436461T3 (fi) 2024-01-16
EP4321513A3 (en) 2024-05-08
PL3436461T3 (pl) 2024-03-18
BR112018069612A2 (pt) 2019-01-22
LT3436461T (lt) 2024-03-12
TWI876724B (zh) 2025-03-11
IL261957B (en) 2022-07-01
HRP20231614T1 (hr) 2024-03-15
CN114456175B (zh) 2024-09-03
JP2024133478A (ja) 2024-10-02
WO2017172596A1 (en) 2017-10-05
MX2018011792A (es) 2019-07-04
TWI828027B (zh) 2024-01-01
AU2017241524A1 (en) 2018-11-15
CN114456176A (zh) 2022-05-10
PH12018502102A1 (en) 2019-07-29
ECSP24026455A (es) 2024-07-31
ECSP18081153A (es) 2019-02-28
JP2023106404A (ja) 2023-08-01
IL293496A (en) 2022-08-01
CN114456176B (zh) 2024-08-30
KR102744951B1 (ko) 2024-12-23
EP4321513A2 (en) 2024-02-14
AU2024201172C1 (en) 2025-09-25
AU2017241524B2 (en) 2021-07-08
SMT202300480T1 (it) 2024-01-10
AU2024201172A1 (en) 2024-03-14
US20210147430A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
ECSP24026455A (es) Compuestos de pirrolotriazina como inhibidores de tam
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
CL2018003511A1 (es) Derivados de pirazolopirimidina como inhibidor de quinasa.
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CU20180006A7 (es) Compuestos de indazaol y azaindazol como inhibidores de irak-4
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
NI201600056A (es) Inhibidores de bromodominio
DOP2017000066A (es) Compuestos y composiciones como inhibidores de quinasa raf
CO2017009298A2 (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
MX372669B (es) Un compuesto que modifica el empalme del gen de foxm1 para usarse en la profilaxis o tratamiento de cáncer.
MX2020010900A (es) Inhibidores de demetilasa-1 especifica de lisina.
NI201500140A (es) Compuestos y composiciones terapéuticos
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
GT201500190A (es) Lactamas fusionadas de arilo y heteroarilo
MX2016014253A (es) Inhibidores de desmetilasa-1 especifica de lisina.
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MX367713B (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
CL2019002079A1 (es) Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611)
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
CL2017000040A1 (es) Inhibidores de aldosterona sintasa.
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1